IP Library › Granted Patent US 9,650,676
Granted Patent B2
US 9,650,676 · App. 14/662,574 · Granted May 16, 2017

Leukocyte MicroRNAS for use in diagnosis and treatment of endometriosis

Inventors: Mitzi Nagarkatti (Columbia, SC); Juhua Zhou (Lexington, SC); Bruce A. Lessey (Greenville, SC); Prakash Nagarkatti (Columbia, SC)
Assignee: University of South Carolina
C12Q1/6883C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,676
App. No.
14/662,574
Granted
May 16, 2017
Kind
B2
Abstract

Methods for diagnosis and treatment of endometriosis are described. Methods utilize the recognition that leukocyte miRNAs can be dramatically dysregulated subjects suffering from endometriosis. Accordingly, leukocyte miRNAs, as well as polynucleotides encoding the miRNAs, can be utilized in the diagnosis and treatment of endometriosis.

Claims (14)

1. A method for diagnosing and/or treating endometriosis in a subject comprising:

obtaining a peripheral blood sample from a subject;

isolating peripheral blood mononuclear cells from the peripheral blood sample;

purifying a total RNA sample from the peripheral blood mononuclear cells;

analyzing the total RNA sample to obtain a quantity of each of a set of leukocyte microRNAs present in the total RNA sample, wherein the set of leukocyte microRNAs comprises microRNA-1246, microRNA-1225-5p, microRNA-223, microRNA-451, microRNA-572, microRNA-143, microRNA-219-1-3p, microRNA-92b, microRNA-148a, microRNA-450a, microRNA-593, microRNA-510, microRNA-1224-5p, microRNA-1290, microRNA-520c-5p, microRNA-1207-5p, microRNA-513a-5p, microRNA-302a, microRNA-675, microRNA-886-5p, microRNA-1297, microRNA-1228, microRNA-505, microRNA-155, microRNA-1281, microRNA-93, microRNA-181a-2 microRNA-181a, microRNA-342-5p, microRNA-21, microRNA-339-3p, microRNA-150, microRNA-17, microRNA-181b, microRNA-501-3p, microRNA-27a, microRNA-23a, microRNA-99b, microRNA-342-3p, microRNA-181a, let-7e, microRNA-769-5p, microRNA-320c, microRNA-1280, microRNA-766, microRNA-339-5p, microRNA-let-7b, microRNA-432, microRNA-125a-5p, microRNA-320a, microRNA-181c, microRNA-140-3p, microRNA-500, and microRNA-146a; and

comparing the quantity of each of the leukocyte microRNAs in the test sample to control quantities of each of the leukocyte microRNAs, wherein a determination that the quantity of each of microRNA-1246, microRNA-1225-5p, microRNA-223, microRNA-451, microRNA-572, microRNA-143, microRNA-219-1-3p, microRNA-92b, microRNA-148a, microRNA-450a, microRNA-593, microRNA-510, microRNA-1224-5p, microRNA-1290, microRNA-520c-5p, microRNA-1207-5p, microRNA-513a-5p, microRNA-302a, microRNA-675, microRNA-886-5p, microRNA-1297, and microRNA-1228 in the test sample is overexpressed as compared to the control quantity of each of these leukocyte microRNAs by factor of about 2 or greater, and each of microRNA-505, microRNA-155, microRNA-1281, microRNA-93, microRNA-181a-2, microRNA-181a, microRNA-342-5p, microRNA-21, microRNA-339-3p, microRNA-150, microRNA-17, microRNA-181b, microRNA-501-3p, microRNA-27a, microRNA-23a, microRNA-99b, microRNA-342-3p, microRNA-181a, let-7e, microRNA-769-5p, microRNA-320c, microRNA-1280, microRNA-766, microRNA-339-5p, microRNA-let-7b, microRNA-432, microRNA-125a-5p, microRNA-320a, microRNA-181c microRNA-140-3p, microRNA-500, and microRNA-146a is underexpressed as compared to the control quantity of each of these leukocyte microRNAs by a factor of about 2 or greater is indicative of endometriosis in the subject; and

diagnosing the subject with endometriosis and/or administering a treatment for the endometriosis to the subject.

2. The method of claim 1 , wherein the test sample is analyzed to obtain a quantity of genetic microRNA, primary microRNA, precursor microRNA and/or mature microRNA.

3. The method of claim 1 , wherein the step of analyzing the test sample to obtain the quantity of the leukocyte microRNA present in the test sample comprises a hybridization-based method.

4. The method of claim 1 , wherein the step of analyzing the test sample to obtain the quantity of the leukocyte microRNA present in the test sample comprises a quantitative real-time PCR method.

5. The method of claim 1 , wherein the step of analyzing the test sample to obtain the quantity of the leukocyte microRNA present in the test sample comprises concentrating or isolating the microRNA from the test sample.

6. The method of claim 1 , wherein the treatment comprises administration of an analgesic.

7. The method of claim 1 , wherein the treatment comprises administration of one or more hormones.

8. The method of claim 1 , wherein the treatment comprises a surgical treatment.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 7, 2015
From: UNIVERSITY OF SOUTH CAROLINA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035379/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2015
From: NAGARKATTI, MITZI; ZHOU, JUHUA; LESSEY, BRUCE A; NAGARKATTI, PRAKASH
To: UNIVERSITY OF SOUTH CAROLINA
Reel/Frame 035204/0946 →
Continuity (2)
Provisional Application 61955519 · Mar 19, 2014
Related Publication 20150267257A1 · Sep 24, 2015